PETAL Consortium Revenue
Hospitals and Health Care • 
Boston, Massachusetts, United States • 1-10 Employees
PETAL Consortium revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Hospitals and Health Care industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Key Contact at PETAL Consortium
Salvia Jain
Founder and Principal Investigator
Company overview
| Headquarters | Boston, Massachusetts, United States |
| Website | |
| NAICS | 62 |
| Keywords | Lymphoma, TCL, Ptcl, Lymphomas, Enktcl, Nk T-Cell Lymphoma, Nk T-Cell Lymphomas, T-Cell Lymphoma, T-Cell Lymphomas, Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma |
| Employees | 1-10 |
About PETAL Consortium
Integrating machine learning and genomics to drive discovery and predict outcomes for newly diagnosed and relapsed/refractory T-cell and NK-cell lymphomas. Connecting oncologists and scientists across the globe to leverage global expertise in tackling these rare and aggressive diseases. PETAL focuses on health disparities by including high-, middle- and low-income countries to capture diverse patient populations to help make access to drugs and education equitable. We @PETAL believe that no patient should be left behind. Our goal at PETAL is to enable personalized treatments to improve patient lives and create an infrastructure through this alliance for future studies including clinical trials to test novel treatments in rare diseases.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
PETAL Consortium has never raised funding before.
Spain
New Zealand
United Kingdom
FranceFrequently asked questions
4.8
40,000 users
